OR WAIT 15 SECS
He is director of The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, and chief medical editor of Ophthalmology Times.
Peter J. McDonnell, MD, discusses how we are eight ways closer to understanding how diseases arise, which could pave the way for new treatments.
Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, and Sjogren’s syndrome afflict an estimated 100 million persons worldwide. As an ophthalmologist, I detest these problems because they frequently cause eye disease; their etiology remains a mystery, and our therapeutic outcomes are often disappointing.
Corticosteroids represent a blunt tool to try to minimize the suffering these bodies endure from their traitorous immune systems and pile on with their well-known side effects. Adding an expensive monoclonal antibody to the marinade might or might not prove helpful in some patients, but any amelioration of the disease certainly comes at the expense of yet more potential therapy-induced adverse reactions.
With dry eye disease in particular, which commonly occurs in the setting of Sjogren’s syndrome, our therapies are substantially better than those used to treat systemic autoimmune disease. Topical corticosteroids often improve signs and symptoms, and we have two FDA-approved agents that work by reducing the injurious effects of T-cells on the lacrimal gland and ocular surface.
Getting closer to understanding
Mountains of data generated by genetic analysis and analyzed by bioinformatics experts using supercomputers are pointing to a potential culprit: Epstein-Barr virus (EBV, HHV-4). A few tantalizing facts:
This indicates that, if EB infection is the inciting mechanism for Sjogren’s syndrome and these other autoimmune disease, it may be possible to block the virus-generated protein from interacting with our human chromosomes and condemning patients to a lifelong struggle with one of these terrible problems.
Future ophthalmologists will no doubt look back at how we treat many patients today and shake their heads at our ignorance. Every generation of doctors does this. Wouldn’t it be great to know why so many people are afflicted with diseases like Sjogren’s syndrome and have a new, specific way to treat them?
Peter J. McDonnell, MDDirector of the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, and chief medical editor of Ophthalmology Times. He can be reached at 727 Maumenee Building 600 N. Wolfe St. Baltimore, MD 21287-9278Phone: 443/287-1511 Fax: 443/287-1514E-mail: firstname.lastname@example.org